# NCT03635892 (NCT03635892)

> A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: cabozantinib plus nivolumab
- Indication: advanced or metastatic non-clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03635892
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Fumarate Hydratase Deficient Renal Cell Carcinoma; Succinate Dehydrogenase Deficient Renal Cell Carcinoma; Collecting Duct Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma
- Interventions: cabozantinib; nivolumab
- Enrollment: 60
- Primary outcome: objective response rate

## Indexed commentary on NCT03635892 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03635892